Video

Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid Tumors

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Youngblood, an epigenetic specialist, says he works regularly with clinicians to look at donated solid tumor samples. The biggest aspect of analysis is to figure out why the T cells aren’t functioning properly. The microenvironment of the cells is also important, as well as determining if the T cells are interacting outside the tumor itself. This all impacts the cells’ endogenous response.

Youngblood says he is working with Stephen Gottschalk, MD, at St. Jude Children’s Research Hospital to characterize the differentiation in chimeric antigen receptor (CAR) T cells. This process involves looking at functional cell responses and defining these at an epigenetic level. With this information, Youngblood says, researchers can decide what the CAR T cells should look like compared with how their samples look. This could eventually be applied to targeted therapy in pediatric solid tumors.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic